Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Big Pharma And Big Biotech Are The New Black

This article was originally published in Scrip

Executive Summary

Unlike the temporary blips of the last year when pharmacy benefit manager Express Scripts Holding Corp. went to war with Gilead Sciences, Inc. on drug pricing, or Federal Reserve chair Yellen warned on the frothy valuations of early-stage biotech companies, this time it is different. Firstly it has lasted longer than previous pull-backs, secondly, like the stock market retrenchment that followed the tragedies of September 11 2001, there is no direct connection with life science stocks, and thirdly, the supposedly unrelated initiating factor – China's slowing economic growth and the bursting of its stock market bubble – was in temporary remission on Thursday and Friday last week but life science stocks still traded off on both days. This time I am afraid that the market means it and as generalists continue to rotate out of life sciences, there are reasons to believe that bigger is going to be better as the investors who are left focus on tangible investment attributes for a change.

You may also be interested in...



Stockwatch: The Lexicon Of Biotech Survival

Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.

Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech

Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.

Stockwatch: GSK And AstraZeneca Rush Into Each Other’s Back Yards

It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel